Clinical trial
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
NCT00023452 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00023452 |
|---|---|
| Title | Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection |
| Official title | TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection |
| Acronym | PREVENT TB |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | US Department of Veterans Affairs U.S. Fed |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Drug |
| Interventions | RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months |
| Enrollment | 8,053 |
| Start date | Jun 1, 2001 |
| Primary completion | Oct 1, 2010 |
| Completion | Sep 1, 2013 |
| First posted | Sep 10, 2001 |
| Last update posted | Aug 27, 2024 |
| Countries | Brazil, Canada, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: